Earnings Releases·Nov 12, 2026, 4:10 PM ET

Sanara MedTech Inc. — Third Quarter 2026 Earnings Summary

Net revenue grew 8% year-over-year to $28.4 million in Q3 2026 and 12% to $84.4 million for the first nine months, driven by a 10% increase in soft tissue repair sales, though operating income declined to $0.7 million in Q3 from $2.9 million in the prior year period.
Full-year 2026 net revenue guidance was lowered to $110 million–$115 million from the previous $116 million–$121 million range, while Adjusted EBITDA rose to $5.6 million in Q3 and $14.9 million for the first nine months.
The company announced a transformational agreement to be acquired by MiMedx Group, Inc., having received shareholder approval in September 2026, with the transaction currently pending regulatory review.
Operating expenses increased 19% in Q3 and 15% for the first nine months, primarily due to $3.0 million and $4.1 million in legal and advisory costs associated with the pending merger, which contributed to a net loss of $1.3 million in Q3 compared to net income of $0.8 million in the prior year.